Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: lean_mass
- Who it enrolls
- age 35 Years to 65 Years; BMI ≥27 required; conditions: Metabolic Syndrome
- Interventions
- Semaglutide, Empagliflozin; Minigastric bypass; Analimentary detoxication; Ramadan fast's weight loss
- Conditions
- Metabolic Syndrome
- Phase and size
- Phase 4 · 220 participants
- Dates
- Start 2024-03-01
Primary completion 2025-09-30 - Sponsor
- University Medical Center, Kazakhstan (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- WeightBaseline, 24 weeks
- Body mass indexBaseline, 24 weeks
- Fat massBaseline, 24 weeks
- Fat free massBaseline, 24 weeks
- blood insulin levelBaseline, 24 weeks
- systolic/diastolic Blood presureBaseline, 24 weeks
- Fasting blood glucoseBaseline, 24 weeks
02Eligibility
Who can take part
Inclusion Criteria: * written informed consent; * T2D≥3-year with glucose lowering therapy including insulin; * 35-55 years old; * BMI≥27 kg/m2 for both sex, for Asian ethnicity; * ongoing treatment with antihypertensive treatment; * weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks. Exclusion Criteria: * T1D; * \<34 age \>56 years old; * unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension); * glomerular filtration rate \<30 mL/min and/or dialysis within 14 days before screening; • malignancy within the past 5 years; * gestation or lactation; * hereditary diseases; * known hypersensitivity to any of the test substances.
03Change log
Registry changes
No changes recorded since the trial was added.